ASA EFFECTS ON ANTIHYPERTENSIVE EFFICACIES OF ENALAPRIL AND LOSARTAN

本研究旨在研究阿司匹林（阿萨）81 mg和325 mg对依那普利和氯沙坦个体降压能力的影响。 次要目的是通过测量尿前列腺素浓度来表征阿萨与氯沙坦或阿萨与依那普利之间观察到的任何相互作用。 零假设是，当低剂量或平均剂量的阿萨加到依那普利或氯沙坦的单药治疗方案中时，血压没有差异。 共招募18名受试者，其中9名接受依那普利或氯沙坦治疗。 本研究包括阿萨81 mg、阿萨324 mg或安慰剂的3.2周治疗期，各间隔2周洗脱期。 将通过袖带测压法采集坐位BP，并完成12小时尿液采集，并分析PGE 2、PGE-M、6-keto-PGF 1 α、2，3-dinor-PGI-M、TXB 2和TX-M。还将采集血浆去甲肾上腺素浓度。 仅当安慰剂和ASA治疗期之间观察到血压存在统计学差异时，才进行尿液和血浆分析和比较。

This research is designed to study the effects of 81 mg and 325 mg of aspirin (ASA) on the individual abilities of enalapril and losartan to lower blood pressure. A secondary objective is to characterize any observed interaction between ASA and losartan or ASA and enalapril by measuring urinary prostanoid concentrations. The null hypothesis is that there is no difference in blood pressure when a low dose or average dose of ASA is added to a monotherapy regimen of either enalapril or losartan. A total of 18 subjects will be recruited, 9 each taking enalapril or losartan. The study involves a 3,2 week treatment periods with either ASA 81 mg, ASA 324 mg or placebo each separated by 2 week washout periods. Sitting BP will be collected via cuff manometry and 12-hour urine collections will be completed and analyzed for PGE2, PGE-M, 6-keto-PGF1alpha, 2,3 dinor-PGI-M, TXB2 and TX-M. Plasma norepinephrine concentrations will also be collected. Urine and plasma analyses and comparisons will only be performed if there is a statistical difference observed in blood pressure between the placebo and ASA-treatment periods.